Diabetes and the Eye

Diabetes: Chronic Complications: Third Edition

Volumn , Issue , 2012, Pages 1-33

  Shotliff, Kevin ^a   Davies, Nigel ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Diabetes; Epidemiology; Eye; Optical coherence tomography (OCT); Retinopathy; Screening; VEGF receptor blockers

Indexed keywords

EID: 84886576032     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118405550.ch1     Document Type: Chapter

References (22)

1. Evans J, Rooney C, Aswood F, Dattani N, Wormald R. Blindness and partial sight in England and Wales. Health Trends 1996;38:5-12.
2. Klein R, Klein BEK, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabet Care 1992;15:1875-1891.
3. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiological Study of Diabetic Retinopathy: II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthal 1984;102:520-526.
4. Kohner EM, Aldington SJ, Stratton IM, et al., United Kingdom Prospective Diabetes Study 30. Diabetic retinopathy at diagnosis of non-insulin dependent diabetes mellitus and associated risk factors. Arch Ophthal 1998;116:297-303.
5. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiological study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthal 1984;102:527-532.
6. Early Treatment Diabetic Retinopathy Study Group. Early photocoagulation for diabetic retinopathy. ETDRS Report number 9. Ophthalmology 1991;98(suppl): 767-785.
7. Freudenstein U, Verne J. A national screening programme for diabetic retinopathy. BMJ 2001;323:4-5.
8. Younis N, Broadbent DM, James M, Harding SP, Vora JP. Incidence of sight threatening retinopathy in patients with type 2 diabetes in the Liverpool diabetic eye study: a cohort study. Lancet 2003;361:195-200.
9. DCCT Research Group. The effect of intensive treatment of diabetes on the development and treatment and progression of long -term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-1034.
10. Stratton IM, Kohner EM, Aldington SJ, et al. Progression of diabetic retinopathy at diagnosis of non -insulin dependent diabetes in the United Kingdom Prospective Diabetes Study. Diabetologia 2001;44:156-163.
11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macro-vascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998;317:703-712.
12. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin -Dependent Diabetes Mellitus. Lancet 1998;351:28-31.
13. Sjølie AK, Klein R, Porta M, et al., DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT -Protect 2): a randomised placebo -controlled trial. Lancet 2008;372: 1385-1393.
14. Klein R, Moss SE, Sinaiko AR, et al. The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin -angiotensin system study. Ophthalmology 2006;113:2231-2236.
15. Keech AC, Mitchell P, Summanen PA, et al., FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-1697.
16. Chew EY, Ambrosius WT, Davis MD, et al., ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244.
17. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003;24:225-248.
18. Colhoun HM, Betteridge DJ, Durrington PN, et al., CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696.
19. Schwartz SG, Flynn HW Jr, Aiello LP. Ruboxistaurin mesilate hydrate for diabetic retinopathy. Drugs Today (Barc) 2009;45:269-274 (Review).
20. Beck RW, Edwards AR, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network (DRCR.net). Three -year follow -up of a randomized trial comparing focal/ grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-251.
21. Nicholson BP, Schachat AP. A review of clinical trials of anti -VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:915-930.
22. Parravano M, Menchini F, Virgili G. Antiangiogenic therapy with anti -vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2009;(4):CD007419.